Breast Cancer Research and Treatment **47**: 303-304, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 47

Adamson E 129
Adhikarakunnathu S 181
Agnarsson BA 121
Arteaga CL 57
Arun B 269

Badia E 71
Bagnasco L 171
Ballaré C 163
Bamberger AM 153
Barbieri O 171
Barkardottir RB 121
Barone D 171
Bauernhofer T 29
Benassai G 91
Berghold A 29
Bertelli G 41
Bianco R 57
Bilgi S 83
Björnsdottir IB 121
Bourstyn E 47
Brackett DJ 63
Brünner N 9

Caponigro F 91
Carola M 91
Ciardiello F 57
Citarella A 91
Collotta A 171
Cosso M 41
Cullen KJ 219
Cusimano E 41

DaCosta SA 269
Damiano V 57
D'Antuono MF 17
Dawkins HJS 17
de Cremoux P 47
Degeorges A 47
Del Giudice ME 111
del Mastro L 41
de Roquancourt A 47
di Isernia G 57
Dixit M 57
Duchesne M-J 71

Edel MJ 17
Egilsson V 121
Ellis MJC 269
Espie M 47
Extra JM 47
Ezzat S 111

Faaland CA 181
Facchini G 91
Fantus IG 111

Garrone O 41
Goodwin PJ 111
Gribaldo L 171
Grøndahl-Hansen J 9
Guido T 41
Gustavino C 41
Guvakova MA 255

Hanas JS 63
Harvey JM 17
Hilsenbeck SG 295
Hollingsworth AB 63
Huang R-P 129

Iaffaioli RV 91

Jenkins SB 269
Jonasson JG 121

Kleinberg DL 201
Krajewska M 129
Krajewski S 129
Kute TE 9

Lackner C 29
Lee AV 295
Lerner MR 63
Lightfoot SA 63
Long R 9

Malt UF 141
Marafante E 171
Marty M 47
Marzano M 91
McCay PB 63
McKeown-Eyssen G 111
Medl M 83
Mirau M 83
Mitchel CA 17
Montagna C 171
Mordoh J 163
Moser R 29

Nicolas J-C 71
Nicolò G 41
Nicosia RF 255
Nolan MK 255

Oates AJ 269
Obermair A 83
Oh Y 283

Page D 111
Papadimitriou JM 17
Parkhouse WS 1
Pearce AA 269
Persico G 91
Peterse HL 101
Peters-Engl C 83
Pollak MN 209
Pons M 71
Portela P 163

Raffaele Bianco A 57
Rasmussen AA 219
Reed JC 129
Robbins PD 17
Rosso R 41
Russell G 9
Rutgers EJTh 101

Sacco MG 171

Samonigg H 29
Santangelo M 91
Schiaffi J 163
Schulte HM 153
Schumaker LM 269
Sciacca L 255
Sepp-Lorenzino L 235
Sevelda P 83
Shao S-M 9
Sigurdsson H 121
Søreide JA 141
Soussi T 47
Strobbe JA 101
Surmacz E 255

Takayama S 129
Thomas T 181
Thomas TJ 181
Thuneke I 153
Tjemsland L 141
Tortora G 57
Tortoriello A 91
Turchi G 171

van Tinteren H 101
Venturini M 41
Vezzoni P 171
Villa A 171

Wang H-G 129
Wanner C 83
Watkins LF 181
Whittal-Strange KS 1
Wijnmaalen A 101
Wilders-Truschnig M 29
Wilkerson KB 63

Yee D 295
Yee D 197
Yomha R 163

Zapata JM 129
Zatloukal K 29
Zucchi I 171

Breast Cancer Research and Treatment **47**: 305-308, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 47

adhesion
effect of IGF-I receptor 255-267
adjuvant therapy
tamoxifen — ultrasound and biopsy for postmenopausal endometrial abnormalities 41-46
Adriamycin
see doxorubicin
angiogenesis
color Doppler ultrasound not correlated with microvessel density 83-89
angiosarcoma
incidence after conservative therapy for invasive cancer 101-109
apoptosis
expression of multiple regulatory proteins in breast cancer cell lines and tumors 129-140

Bcl-2
expression of multiple apoptosis-regulatory proteins in breast cancer cell lines and tumors 129-140
blood vessel area and density
by image analysis — no association with nodal status 17-27
BRCA2
inherited BRCA2 mutation and higher S-phase, histologic grade 121-127
breast-conserving therapy
incidence of subsequent angiosarcoma 101-109

cAMP-dependent protein kinase A
control by TGFα-EGFR autocrine pathway 57-62
caspase-3
expression of multiple apoptosis-regulatory proteins in breast cancer cell lines and tumors 129-140
cathepsin D
in prognosis, with PAI-1 9-16
CD44
soluble v5 and v6 variants in serum vs. metastasis 29-40
cell lines
a new hormone-responsive mammary carcinoma cell line, MG1361, from MMTV-neu transgenic mice 171-180
see also individual cell line names
chemosensitivity
see predictive factors
computer-assisted video analysis
of breast tumor vascularity — no association with nodal status 17-27
conservative therapy
incidence of subsequent angiosarcoma 101-109
cytokines
expression of leukemia inhibitory factor in breast cancer cells and modulation by progestins 153-161

DMBA rat mammary tumors
prevention by leuprolide vs. tamoxifen vs. oophorectomy 63-70
DNA methylation
4-hydroxytamoxifen irreversibly silences an estrogen response by gene methylation 71-81
Doppler ultrasound
correlation with tumor size and nodal status, but not microvessel density 83-89
doxorubicin
additive cytotoxicity with MAb FC-2.15 (anti-Lewis^x) in resistant cells 163-170
drug resistance
additive activity of monoclonal antibody FC-2.15 (anti-Lewis^x) in resistant cells 163-170
drug sensitivity
see predictive factors

E-cadherin-dependent cell adhesion
effect of IGF-I receptor 255-267
endocrine therapy
IGF-I, IGFBPs as potential targets 209-217
endometrial biopsy
and ultrasound for postmenopausal endometrial abnormalities on tamoxifen 41-46

epidermal growth factor (EGF) receptor
control of type I cAMP-dependent protein kinase A 57-62
epigenetic modifications
4-hydroxytamoxifen irreversibly silences an estrogen response by gene methylation 71-81
estrogen
induction of p21 and growth inhibition by estradiol in MCF-10A cells with transfected ER 181-193
estrogen receptor
crosstalk with IGF-I receptor 255-267
not involved in exercise reduction of NMU tumorigenesis 1-8
exercise
and reduction of NMU mammary tumorigenesis 1-8

FC-2.15 (monoclonal anti-Lewis^x)
additive cytotoxicity with paclitaxel, doxorubicin in resistant cells 163-170

gonadotropin-releasing hormone (GnRH) agonists
leuprolide vs. tamoxifen vs. oophorectomy in prevention of DMBA rat tumors 63-70
growth hormone
and IGF-I — role in normal mammary development 201-208

hereditary breast cancer
inherited BRCA2 mutation and higher S-phase, histologic grade 121-127
histologic grade
higher in tumors with inherited BRCA2 mutation 121-127
hormone response
of the new MG1361 mammary tumor cell line from MMTV-neu transgenic mice 171-180

IGF binding proteins (IGFBPs)
and IGF-independent growth inhibition 283-293
IGF-I
in normal mammary development 201-208
IGF-I receptor
and E-cadherin-dependent cell adhesion 255-267
crosstalk with estrogen receptor 255-267
IGF-I receptor (*cont.*)
not involved in exercise reduction of NMU tumorigenesis 1-8
structure and functional domains 235-253
IGF-II/mannose-6-phosphate receptor
and invasive potential of breast cancer cells 219-233
as a putative tumor suppressor gene 269-281
IGFBP-3
as a possible risk factor for premenopausal breast cancer 111-120
IGFs
endocrine effects of circulating IGF-I, IGFBPs and breast cancer prevention 209-217
special issue 197-302
system components as prognostic factors 295-302
image analysis
of breast tumor vascularity — no association with nodal status 17-27
insulin
as a risk factor for premenopausal breast cancer 111-120
insulin receptor
in comparison with IGF-I receptor structure and functional domains 235-253
insulin-like growth factors
see IGFs

leukemia inhibitory factor (LIF)
expression in breast cancer cells and modulation by progestins 153-161
leuprolide
vs. tamoxifen, oophorectomy, in DMBA rat tumor prevention 63-70

mammary development
role of IGF-I 201-208
mannose-6-phosphate/IGF-II receptor
and invasive potential of breast cancer cells 219-233
as a putative tumor suppressor gene 269-281
MCF-10A cells
with transfected ER — induction of p21 and growth inhibition by estradiol 181-193
MDA-468 human breast cancer cells
control of cAMP-dependent protein kinase A by TGFα-EGFR autocrine pathway 57-62

metastasis
and soluble CD44 v5 and v6 variants in serum 29-40
methylation
4-hydroxytamoxifen irreversibly silences an estrogen response by gene methylation 71-81
MG1361
a new hormone-responsive mammary tumor cell line from MMTV-neu transgenic mice 171-180
microvessel density
not correlated with blood flow by color Doppler ultrasound 83-89
MMTV-neu transgenic mice
derivation of a new mammary carcinoma cell line, MG1361 171-180
monoclonal antibody FC-2.15 (anti-Lewis^x)
additive cytotoxicity with paclitaxel, doxorubicin in resistant cells 163-170

Navelbine
see vinorelbine
neu transgenic mice
derivation of a new mammary carcinoma cell line, MG1361 171-180
NMU rat mammary tumors
reduction by prior exercise 1-8
nodal status
no association with tumor vascularity by image analysis 17-27

p21 cdk inhibitor
induction and growth inhibition by estradiol in MCF-10A cells with transfected ER 181-193
p53
and possible radio resistance 47-55
no correlation with adjuvant CMF DFS 47-55
paclitaxel
additive cytotoxicity with MAb FC-2.15 (anti-Lewis^x) in resistant cells 163-170
phase I/II trial with vinorelbine 91-97
paracrine regulation
IGF-II in stromal cells surrounding malignant breast epithelium 219-233
pelvic ultrasound
and biopsy for postmenopausal endometrial abnormalities on tamoxifen 41-46
plasminogen activator inhibitor type 1 (PAI-1)
in prognosis, with cathepsin D 9-16
posttraumatic stress disorder
incidence and correlates after breast cancer surgery 141-151
predictive factors
p53 — no correlation with adjuvant CMF DFS 47-55
prevention
by leuprolide vs. tamoxifen vs. oophorectomy in DMBA rat model 63-70
IGF-I, IGFBPs as potential targets 209-217
progesterone receptor
and induction of leukemia inhibitory factor (LIF) 153-161
prognosis
color Doppler ultrasound not correlated with microvessel density 83-89
IGF system components 295-302
low cathepsin D and low PAI-1 define good node-negative prognosis 9-16
proteases
cathepsin D, uPA, uPAR, and PAI-1 in prognosis 9-16
protein kinase A, cAMP dependent
control by TGFα-EGFR autocrine pathway 57-62
psychosocial function
incidence and predictors of posttraumatic stress after breast cancer surgery 141-151

radiation therapy
in breast-conservation — incidence of subsequent angiosarcoma 101-109
p53 mutation and possible radio resistance 47-55
risk factors
circulating IGF-I 209-217
insulin, IGFBP-3 elevated in premenopausal breast cancer 111-120

S-phase
higher in tumors with inherited BRCA2 mutation 121-127
serum markers
soluble CD44 v5 and v6 variants in serum vs. metastasis 29-40

signal transduction
IGF-I receptor structure and functional domains 235-253
stromal cells
IGF-II in cells surrounding malignant breast epithelium 219-233
surgery
incidence and predictors of posttraumatic stress after breast cancer surgery 141-151

tamoxifen
4-hydroxytamoxifen irreversibly silences an estrogen response by gene methylation 71-81
ultrasound and biopsy for postmenopausal endometrial abnormalities 41-46
vs. leuprolide, oophorectomy, in DMBA rat tumor prevention 63-70
Taxol
see paclitaxel
tumor suppressor genes
mannose-6-phosphate/IGF-II receptor as a candidate 269-281

ultrasound
and biopsy for postmenopausal endometrial abnormalities on tamoxifen 41-46
urokinase plasminogen activator (uPA)
and uPAR, PAI-1, cathepsin D in prognosis 9-16

vascularity
by computer image analysis — no association with nodal status 17-27
vinorelbine
phase I/II trial with paclitaxel 91-97